Levosimendan Auxilia (Levosimendan)

Levosimendan is indicated for conditions involving acute cardiac dysfunction where enhanced contractility and vasodilation are required.

• Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
• Cardiogenic shock: provides rapid inotropic support and vasodilation to stabilize systemic perfusion.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing after‑load, which together improve cardiac performance in acute heart failure states.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drop in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Tachycardia: increased heart rate.
• Dizziness: feeling of light‑headedness.
• Arrhythmias: non‑sustained ventricular ectopy.

Serious or Rare Side Effects

• Severe hypotension: may require vasopressor support.
• Myocardial ischemia: chest pain or ECG changes.
• Sustained ventricular arrhythmias: life‑threatening rhythm disturbances.
• Anaphylactic reactions: rare but possible hypersensitivity.
• Hepatic enzyme elevation: significant increase in transaminases.
• Thrombocytopenia: marked reduction in platelet count.

Levosimendan requires careful monitoring and specific handling precautions.

• Blood pressure monitoring: observe for hypotension during infusion.
• Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders.
• Dose adjustment: consider reduced dosing in severe renal or hepatic impairment.
• Contraindication awareness: avoid use in patients with uncontrolled severe hypotension.
• Caution with concurrent vasodilators: may potentiate blood pressure lowering effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Potent vasodilators (e.g., nitroglycerin): risk of profound hypotension.
• Other inotropes (e.g., dobutamine): increased likelihood of arrhythmias.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise levosimendan plasma levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt the inotropic response.
• Diuretics: can exacerbate volume depletion and hypotension.
• ACE inhibitors or ARBs: additive blood pressure‑lowering effect.
• Calcium channel blockers: potential hemodynamic interactions.
• Anticoagulants: monitor for bleeding if hypotension occurs.